@entity1151 ( @entity1151 ) is common and the majority of @entity1 survive the acute event. Survivors are at increased risk for adverse outcomes, including persistent thrombi, recurrent @entity887 , @entity120 ( @entity120 ), and @entity204 . Anticoagulation protects against recurrence, which has a high mortality rate. The recommended duration of anticoagulation for @entity1 with reversible @entity1151 risk factors is 3 months. For @entity1 with idiopathic @entity1151 or persistent risk factors, extended duration of anticoagulation is preferred, balanced with an individual @entity1 's risk of @entity548 , which in itself is a major cause of morbidity and mortality. Among @entity1 with @entity5 who develop @entity1211 ( @entity1211 ), low-molecular-weight heparin is preferred over oral @entity2067 antagonists in the first 6 months. Thereafter, anticoagulation should be continued indefinitely with either low-molecular-weight heparin or oral @entity2067 antagonists. Inferior vena cava filters are not routinely recommended and should only be used in @entity1 who have a contraindication to anticoagulation. @entity1 who have had @entity1211 and with persistent or recurrent @entity1353 should be evaluated for recurrence of @entity1211 or development of @entity120 . @entity1 with recurrent @entity1211 should be anticoagulated indefinitely. Routine screening for @entity120 in asymptomatic @entity1 is not recommended. Echocardiography often provides the first indication of the presence of @entity120 . Once presence of @entity120 is established by right-sided heart catheterization and perfusion imaging (ie, ventilation/perfusion scintigraphy, computed tomography angiography, or pulmonary angiography), @entity1 should be referred early to a center with expertise, as it is potentially surgically curable by pulmonary endarterectomy. Those who are deemed inoperable after being evaluated may gain symptomatic benefit from drugs approved for @entity8577 . Lung transplantation may also be an option for @entity1 who are not candidates for pulmonary endarterectomy.

Evaluation and management of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['dyspnea'] @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension', 'chronic thromboembolic pulmonary hypertension', 'CTEPH'] @entity8577 :: ('MESH:D065627', 'Disease') :: ['idiopathic pulmonary arterial hypertension'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['Pulmonary embolism', 'PE'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1151 :: (MESH:D011655,Disease) :: ['chronic pulmonary thromboembolic disease']
